Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
WIN-Partners Co., Ltd. (3183.T)
Tokyo, JP
Established in 1973 and headquartered in Tokyo, Japan, WIN-Partners Co., Ltd. leverages its subsidiaries to distribute a comprehensive range of medical devices to healthcare institutions, primarily across Japan. Its diverse product offerings include cutting-edge cardiovascular tools such as percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters. The company also supplies devices for cardiac rhythm management, like pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters. Furthermore, WIN-Partners provides structural and peripheral vascular products, including stent grafts, transcatheter heart valves, mechanical heart valves, and various stents and embolic coils. Rounding out its portfolio are diabetes management systems such as insulin pumps and continuous glucose monitoring devices, in addition to magnetic resonance imaging equipment.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.28% | -2.97% | -6.78% | -15.40% | -5.47% | -9.10% | -5.69% | +20.90% | +20.78% | +60.45% | +1,019.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+11.0% ★ Q1'26: +15.0% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+7.9% ★ Q1'26: +0.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+2.9% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+3.3% ★ Q1'26: +3.3% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+25.7% ★ Q1'26: +28.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-2.7% ★ Q1'26: -3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.21× ★ Q1'26: 0.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
|---|---|---|
| Revenue |
50.56B
est: 47.00B (+7.6%)
|
54.15B
est: 50.00B (+8.3%)
|
| EBITDA |
2.88B
est: 1.90B (+51.7%)
|
3.37B
est: 2.02B (+67.0%)
|
| EBIT |
2.60B
est: 1.77B (+46.8%)
|
3.09B
est: 1.88B (+64.1%)
|
| Net Income |
1.69B
est: 1.40B (+21.0%)
|
2.11B
est: 1.60B (+32.2%)
|
| SGA |
4.10B
est: 4.13B (-0.8%)
|
4.30B
est: 4.39B (-2.1%)
|
| EPS |
58.87
est: 48.75 (+20.8%)
|
73.56
est: 55.75 (+31.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 33.1K | 0.45% |
| 2 | iShares Core TOPIX ETF 1475.T | 0.00% | 347.6K | 0.05% |
| 3 | Dimensional - International Small Cap ETF DFIS | 0.00% | 801.80 | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideumi Akizawa | President, Chief Executive Officer & Chairman | — | male |
| Hiromi Mitagami | Director, Operating Officer & GM of Sales Management Department | — | male |
| Keiji Matsumoto | Director, Executive Officer and GM of Administration Headquarters, General Affairs & System Dev. | — | male |
| Yuji Akita | Executive Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3183.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
